Clinical trials are now underway
At Siolta Therapeutics, we are leveraging our knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted human microbiome therapeutics for the prevention and treatment of chronic inflammatory diseases, starting with allergic disease. We are currently in a Phase Ib clinical trial for the evaluation of our lead candidate, STMC-103H.
Microbiome-based diagnostics will support our pursuit of precision medicine.
In addition to microbial therapeutics, we are employing the comprehensive data collected in our clinical studies to develop companion diagnostics and biomarker assays that can help clinicians identify those patients who will benefit most from intervention with our live biotherapeutic products.